SAFETY AND EFFICACY OF PROTRACTED USAGE OF ORAL ANTIDIABETIC DRUGS IN TYPE-2 DIABETES MANAGEMENT
DOI:
https://doi.org/10.22159/ajpcr.2025v18i7.55415Keywords:
Diabetes,, Oral anti diabetic drugs, Insulin, Metformin, Glimepiride, DPP4 inhibitorsAbstract
This review paper explores the impact of prolonged usage of oral antidiabetic drugs, particularly focusing on the therapeutic benefits and adverse effect associated with long-term consumption of these medications. Diabetes mellitus is becoming increasingly common worldwide, with 415 million adults diagnosed in 2015 and an anticipated increase to 642 million by 2040. Successfully treating type 2 diabetes typically involves a multi-faceted approach, targeting both insulin resistance and impairing the function of endocrine beta-cell using multiple medications. Although metformin is commonly regarded as the primary oral medication for diabetes management, it may not always provide adequate control, prompting the need for supplementary therapies to enhance its efficacy. Among the various oral antidiabetic agents available, sulfonylureas, such as glimepiride, remain a popular choice as a second-line add-on to metformin, particularly in Indian clinical settings. Compared to conventional sulfonylureas like glibenclamide, modern sulfonylureas like glimepiride have shown improved outcomes and better safety profiles. Glimepiride has been extensively studied and has a large body of evidence supporting its use. Nevertheless, antidiabetic medications have shown limited success in attaining ideal blood sugar control, with merely 41% of individuals reaching the intended goals. Additionally, questions have been raised regarding the possible harmful effects and adverse reactions of these drugs, such as increased body weight, decreased bone density, and heightened risk of heart-related issues. The use of sulfonylureas has been linked to heightened risks of low blood sugar, increased body mass, and harm to the cardiovascular system. In contrast, usage of metformin may lead to digestive system discomfort. Despite potential risks, the advantages of these drugs, including better blood sugar management, kidney protection, and fewer diabetes-related complications, generally surpass the possible drawbacks when used carefully. In response to these issues, scientists have investigated alternative strategies to reduce long-term use of antidiabetic medications.
Downloads
References
Kumari M, Singh R. Evaluation of safety and efficacy of glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus: Analytical study.. 2020;2: ???.
Devarajan TV, Venkataraman S, Kandasamy N, Oomman A, Boorugu HK, Karuppiah S, et al. Comparative evaluation of safety and efficacy of glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus. Indian J Endocrinol Metab. 2017;21:745-50.
Oyagbemi AA, Salihu MN, Oguntibeju OO, Esterhuyse AJ, Farombi EO. Some Selected Medicinal Plants with Antidiabetic Potentials. London: IntechOpen;. doi: 10.5772/57230
Salsali A, Nathan M. A review of types 1 and 2 diabetes mellitus and their treatment with insulin. Am J Ther. 2006;13(4):349-61. doi: 10.1097/00045391-200607000-00012
Ferreira-da-Silva FW, da Silva-Alves KS, Lemos-Dos-Santos M, de Oliveira KA, Joca HC, do Vale OC, et al. n5-STZ diabetic model develops alterations in sciatic nerve and dorsal root ganglia neurons of Wistar rats. ISRN Endocrinol. 2013;2013:638028. doi: 10.1155/2013/638028
Steenkamp DW, Alexanian SM, Sternthal E. Approach to the patient with atypical diabetes. Can Med Assoc J. 2014;186(9):678-84. doi: 10.1503/cmaj.130185, PMID 24396100
DasNandy A, Patil VS, Hegde HV, Harish DR, Roy S. Elucidating type 2 diabetes mellitus risk factor by promoting lipid metabolism with gymnemagenin: An in vitro and in silico approach. Front Pharmacol. 2022;13:1074342. doi: 10.3389/fphar.2022.1074342, PMID 36582536
Palmer BF, Naderi AS. Metabolic complications associated with use of thiazide diuretics. J Am Soc Hypertens. 2007;1:381-92. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus [review of the pathophysiology of gestational diabetes mellitus]. Int J Mol Sci. 2018;19(11):3342. doi: 10.3390/ijms19113342
Palmer BF, Naderi AS. Metabolic complications associated with use of thiazide diuretics. J Am Soc Hypertens. 2007;1(6):381-92. doi: 10.1016/j.jash.2007.07.004
Cobelli C, Man CD, Sparacino G, Magni L, De Nicolao GD, Kovatchev BP. Diabetes: Models, signals, and control. IEEE Rev Biomed Eng. 2009;2:54-96. doi: 10.1109/RBME.2009.2036073, PMID 20936056
Cefalu WT. Primary prevention of type 2 diabetes: There are no simple solutions! Diabetes. 2009 Jul 28;58(8):1730-1. doi: 10.2337/db09- 0840, PMID 19638532
Papatheodorou K, Banach M, Bekiari E, Rizzo M, Edmonds M. Complications of diabetes 2017. J Diabetes Res. 2018;2018:3086167. doi: 10.1155/2018/3086167, PMID 29713648
Das D, Biswas SK, Bandyopadhyay S. A critical review on diagnosis of diabetic retinopathy using machine learning and deep learning. Multimed Tools Appl. 2022;81(18):25613-55. doi: 10.1007/s11042- 022-12642-4, PMID 35342328
Singer DE, Nathan DM, Fogel HA, Schachat AP. Screening for diabetic retinopathy. Ann Intern Med. 1992;116(8):660-71. doi: 10.7326/0003- 4819-116-8-660, PMID 1546868
Selvarajah D, Kar D, Khunti K, Davies MJ, Scott AR, Walker J, et al. Diabetic peripheral neuropathy: Advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol. 2019;7(12):938-48. doi: 10.1016/S2213-8587(19)30081-6, PMID 31624024
Candrilli SD, Davis KL, Kan HJ, Lucero MA, Rousculp MD. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications. 2007;21(5):306-14. doi: 10.1016/j.jdiacomp.2006.08.002, PMID 17825755
Casellini CM, Vinik AI. Recent advances in the treatment of diabetic neuropathy. Curr Opin Intern Med. 2006;5(3):260-6. doi: 10.1097/01. med.0000216963.51751
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes. Diabetologia. 2018;61(12):2461-98. doi: 10.1007/s00125-018-4729-5, PMID 30288571
Davies M, Brophy S, Williams R, Taylor AG. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes. 2006;29(7):1518-22. doi: 10.2337/dc05-2228, PMID 16801572
Dharani B, Sebastian S, Nazrin S, A. Preventing diabetic kidney disease: A systematic review of current pharmacological approaches. Int J Appl Pharm. 2025;17(1):68-81. doi: 10.22159/ijap.2025v17i1.52956
Lea JP, Nicholas SB. Diabetes mellitus and hypertension: Key risk factors for kidney disease. J Natl Med Assoc. 2002;94(8) Suppl:7S-15. PMID 12152917
Min TZ, Stephens MW, Kumar P, Chudleigh RA. Renal complications of diabetes. Br Med Bull. 2012;104(1):113-27. doi: 10.1093/bmb/ lds030
Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998;352(9123):213-9. doi: 10.1016/S0140- 6736(98)01346-4, PMID 9683226
Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease [review of diabetes and vascular disease]. Circulation. 2003;108(12):1527-32. doi: 10.1161/01.CIR.0000091257.27563.32, PMID 14504252
Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: The Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes. 2006;55(5):1463-9. doi: 10.2337/db05-1423, PMID 16644706
Costacou T, Orchard TJ. Cumulative kidney complication risk by 50 years of type 1 diabetes: The effects of sex, age, and calendar year at onset. Diabetes Care. 2018;41(3):426-33. doi: 10.2337/dc17-1118, PMID 28931542
Brown WV. Risk factors for vascular disease in patients with diabetes [Review of Risk factors for vascular disease in patients with diabetes]. Diabetes Obes Metab. 2000;2:11-8. doi: 10.1046/j.1463- 1326.2000.00001
Makroum MA, Adda M, Bouzouane A, Ibrahim H. Machine learning and smart devices for diabetes management: Systematic review. Sensors (Basel). 2022;22(5):1843. doi: 10.3390/s22051843, PMID 35270989
Ellahham S. Diabetes and its associated cardiovascular complications in the Arabian Gulf: Challenges and opportunities. Clin Exper Cardiol. 2020;11(2):1.
Mosenzon O, Cheng AY, Rabinstein AA, Sacco S. Diabetes and stroke: What are the connections? [Review of diabetes and stroke: What are the connections?]. J Stroke. 2023;25(1):26-38. doi: 10.5853/ jos.2022.02306, PMID 36592968
Smith SR, Ruiz CW, Ali S, Kim CJ, Murchie MS, Crossman SH, et al. A pharmacist-led collaborative care model for cardiometabolic risk reduction: A case study. ADCES Pract. 2021;9(3):16-23. doi: 10.1177/2633559X21994855
Gibbons GW, Shaw PM. Diabetic vascular disease: Characteristics of vascular disease unique to the diabetic patient. Semin Vasc Surg. 2012;25(2):89-92. doi: 10.1053/j.semvascsurg.2012.04.005, PMID 22817858
AQ10 Nathan DM. Long-term complications of diabetes mellitus. 2023.
Nathan DM, Genuth S, Lachin JM, Cleary PA, Crofford OB, Davis JL, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86. doi: 10.1056/ NEJM199309303291401, PMID 8366922
Tay S, Abdulnabi S, Saffaf O, Harroun N, Yang C, Semenkovich CF, et al. Comprehensive assessment of current management strategies for patients with diabetes and chronic limb-threatening ischemia. Clin Diabetes. 2021;39(4):358-88. doi: 10.2337/cd21-0019, PMID 34866779
Duarte AM, Guarino MP, Barroso S, Gil MM. Phytopharmacological strategies in the management of type 2 diabetes mellitus. Foods. 2020;9(3):271. doi: 10.3390/foods9030271, PMID 32131470
Rosenkranz B, Profozić V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39(12):1617-24. doi: 10.1007/s001250050624, PMID 8960852
Garber AJ, Bruce S, Fiedorek FT. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: An open-label extension study. Clin Ther. 2002;24(9):1401-13. doi: 10.1016/s0149-2918(02)80044-3, PMID 12380632
Alam S, Bishal A, Bandyopadhyay B. Formulation and evaluation of metformin hydrochloride sustained release matrix tablets. Int J Curr Pharm Res. 2021;13(5):82-8. doi: 10.22159/ijcpr.2021v13i5.1899
Darusman F, Rusdiana T, Sopyan I, Yuliar NF, Aryani R. Bioequivalence of metformin as an oral antidiabetic: A systematic review. Int J Appl Pharm. 2023;15(6):76-81. doi: 10.22159/ijap.2023v15i6.49142
Spencer M, Yang L, Adu A, Finlin BS, Zhu B, Shipp LR, et al. Pioglitazone treatment reduces adipose tissue inflammation through reduction of mast cell and macrophage number and by improving vascularity. PLoS One. 2014;9(7):e102190. doi: 10.1371/journal. pone.0102190, PMID 25010722
Coulibaly AY, Hashim R, Sombié PA, Sulaiman SF, Sulaiman O, Ang LZ, et al. In vitro antihyperglycemic and chelating potential of selected ayurvedic medicinal plants. Indian J Pharm Sci. 2020;82(3). doi: 10.36468/pharmaceutical-sciences.672
Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am. 1997;26(3):539-51. doi: 10.1016/s0889-8529(05)70266-8, PMID 9314014
Neumiller JJ. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2012;46(3):358-67. doi: 10.1345/aph.1Q522, PMID 22318932
Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol. 2019;10:389. doi: 10.3389/fendo.2019.00389, PMID 31275246
Krishnan A, Shankar M, Lerma EV, Wiegley N. Sodium glucose cotransporter 2 (SGLT2) inhibitors and CKD: Are you a #Flozinator? Kidney Med. 2023;5(4):100608. doi: 10.1016/j.xkme.2023.100608, PMID 36915368
Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66(1):255-70. doi: 10.1146/annurev-med-051013-110046, PMID 25341005
Boussery K, Belpaire FM, Voorde JV. Physiological aspects determining the pharmacokinetic properties of drugs. In: The Practice of Medicinal Chemistry. 3rd ed. Academic Press eBooks. United States: Academic Press; 2008. p. 637. Available from: https://biblio.ugent.be/ publication/438229
Curry SH, Whelpton R. Drug Administration and Distribution. United States: Wiley; 2010. p. 23-51. doi: 10.1002/9780470665190.ch2
Sadgrove NJ, Jones GL. From Petri dish to patient: Bioavailability estimation and mechanism of action for antimicrobial and immunomodulatory natural products. Front Microbiol. 2019;10:2470. doi: 10.3389/fmicb.2019.02470, PMID 31736910
Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602-13. doi: 10.7326/0003-4819-154-9- 201105030-00336, PMID 21403054
Chamberlain JJ, Herman WH, Leal S, Rhinehart AS, Shubrook JH, Skolnik N, et al. Pharmacologic therapy for type 2 diabetes: Synopsis of the 2017 American Diabetes Association standards of medical care in diabetes. Ann Intern Med. 2017;166(8):572-8. doi: 10.7326/M16-2937, PMID 28288484
Li YJ, Chang YL, Chou YC, Hsu CC. Hypoglycemia risk with inappropriate dosing of glucose-lowering drugs in patients with chronic kidney disease: A retrospective cohort study. Sci Rep. 2023;13(1):6373. doi: 10.1038/s41598-023-33542-z, PMID 37076583
Packer M. Potentiation of insulin signaling contributes to heart failure in type 2 diabetes [review of potentiation of insulin signaling contributes to heart failure in type 2 diabetes]. JACC Basic Transl Sci. 2018;3(3):415-9. doi: 10.1016/j.jacbts.2018.04.003, PMID 30062227
Gallwitz B, Giorgino F. Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide. Front Endocrinol. 2021;12:645507. doi: 10.3389/fendo.2021.645507, PMID 34267725
Weinberg MM, Froum SJ, Segelnick SL. Introduction to Pharmacology. United States: Wiley; 2020. p. 1-12. doi: 10.1002/9781119539384
Pappachan JM. Efficacy and cardiovascular safety of antidiabeticmedications. Curr Drug Saf. 2021;16(2):115-21. doi: 10.2174/1574886 316666210112153429, PMID 33438554
Saini V. Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes. 2010;1(3):68-75. doi: 10.4239/wjd.v1.i3.68, PMID 21537430
Anchit, Bhushan A, B S. Effect of metformin monotherapy and combination therapy with glimepiride on lipid profile in drug naive type-2 diabetes patients: A prospective observational study. J Pharm Care. 2023. doi: 10.18502/jpc.v11i1.12633
Zeng Z, Huang SY, Sun T. Pharmacogenomic studies of current antidiabetic agents and potential new drug targets for precision medicine of diabetes. Diabetes Ther. 2020;11(11):2521-38. doi: 10.1007/s13300- 020-00922-x, PMID 32930968
McCall AL. Clinical review of glimepiride. Expert Opin Pharmacother. 2001;2(4):699-713. doi: 10.1517/14656566.2.4.699, PMID 11336617
Harding EA, Finch AJ, Dunne MJ. Blockade of K+ channels in insulin-secreting cells by the “potassium channel opener” SDZ PCO 400. Biochem Soc Trans. 1993;21(4):402S. doi: 10.1042/bst021402s, PMID 8131978
Müller G. The mode of action of the antidiabetic drug glimepiride-beyond insulin secretion. Curr Med Chem Immunol Endocr Metab Agents. 2005;5(6):499-518. doi: 10.2174/156801305774962123
Basit A, Riaz M, Fawwad A. Glimepiride: Evidence-based facts, trends, and observations (GIFTS). Vasc Health Risk Manag. 2012;8:463-72. doi: 10.2147/HIV.S33194, PMID 23028231
Song Y, Wu Z, Zhao P. The effects of metformin in the treatment of osteoarthritis: Current perspectives. Front Pharmacol. 2022;13:952560. doi: 10.3389/fphar.2022.952560, PMID 36081941
Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways [Review of metformin pathways]. Pharmacogenet Genomics. 2012;22(11):820-7. doi: 10.1097/FPC.0b013e3283559b22, PMID 22722338
Graham GG. Clinical pharmacokinetics of metformin. 2024;1. PMID 2124107068. Vigneri R, Goldfine ID. Role of metformin in treatment of diabetes mellitus. Diabetes Care. 1987;10(1):118-22. doi: 10.2337/ diacare.10.1.118, PMID 3552509
Wińska K, Mączka W, Gabryelska K, Grabarczyk M. Mushrooms of the genus Ganoderma Used to treat diabetes and insulin resistance. Molecules. 2019;24(22):4075. doi: 10.3390/molecules24224075, PMID 31717970
Giannarelli R, Aragona M, Coppelli A, Del Prato SD. Reducing insulin resistance with metformin: The evidence today. Diabetes Metab. 2003;29(4 Pt 2):6S28-35. doi: 10.1016/s1262- 3636(03)72785-2, PMID 14502098
Maki MK, Manivannan N. LBODP038 metformin-associated severe lactic acidosis: A case study of the perfect storm. J Endocr Soc. 2022;6 Suppl 1:A267. doi: 10.1210/jendso/bvac150.548
Pham TK, Nguyen TH, Yi JM, Kim GS, Yun HR, Kim HK, et al. Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice. Exp Mol Med. 2023;55(4):767-78. doi: 10.1038/s12276-023-00958-6, PMID 37009790
Chen X, Zheng Y, Shen Y. Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors. Curr Med Chem. 2006;13(1):109-16. doi: 10.2174/092986706789803035, PMID 16457643
Dabhi AS, Bhatt NR, Shah MJ. Voglibose: An alpha glucosidase inhibitor. J Clin Diagn Res. 2013;7(12):3023-7. doi: 10.7860/ JCDR/2013/6373.3838, PMID 24551718
Dabhi AS, DNR. Voglibose: An alpha glucosidase inhibitor. BMJ S. 2023. PMCID PMC3919386
Kishimoto M. Teneligliptin: A DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2013;6:(187-95). doi: 10.2147/DMSO.S35682, PMID 23671395
Koo H, Yu T, Lee DH. The nonglycemic actions of dipeptidyl peptidase-4 inhibitors [review of the nonglycemic actions of dipeptidyl peptidase-4 inhibitors]. BioMed Res Int. 2014;2014:1. doi: 10.1155/2014/368703
Published
How to Cite
Issue
Section
Copyright (c) 2025 B. Durga1
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
